Abstract: The present disclosure provides, in an aspect, a computer-implemented method for modifying vehicle settings for a vehicle, the method comprising identifying a vehicle occupant having a personalized set of vehicle settings for the vehicle, identifying a condition modifier associated with the vehicle occupant and the personalized set of vehicle settings, and applying a vehicle setting from the set of vehicle settings based on the condition modifier.

Abstract: The present disclosure relates to single-ended-to-differential amplifiers and radio frequency receivers. One example single-ended-to-differential amplifier includes a first inverting amplifier, a second inverting amplifier, and a third inverting amplifier. Both an input end of the first inverting amplifier and an input end of the second inverting amplifier are coupled to an input end of the single-ended-to-differential amplifier, an output end of the first inverting amplifier is coupled to an input end of the third inverting amplifier, an output end of the second inverting amplifier is coupled to a first output end of the single-ended-to-differential amplifier, and an output end of the third inverting amplifier is coupled to a second output end of the single-ended-to-differential amplifier. An impedance element is coupled between the input end of the first inverting amplifier and the output end of the first inverting amplifier.

Abstract: An electronic module assembly is provided. The electronic module assembly may include one or more processors mounted to a laminate, a top frame mounted to the laminate and surrounding the one or more processors, and a removable lid covering the one or more processors. The removable lid includes latches arranged along a perimeter of the removable lid, the latches engage with a lip of the top frame and secure the removable lid to the module assembly, and the removable lid can only be removed from the module assembly by releasing all of the latches.

Abstract: An electronic assembly is provided. The electronic assembly may include an electronic module mounted to a laminate, a cooling apparatus directly above the module, a single thermal interface material positioned between and directly contacting the module and the cooling apparatus, and a rotating cover rotatably attached to a top frame secured to the laminate, wherein the rotating cover includes an open position and a closed position.

Abstract: A pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein, use of the pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases, and use of the pharmaceutical composition for immunomodulation.

Abstract: A knitted component having a first region located adjacent to a perimeter edge of the article, where the first region of the knitted component includes an inner surface and an outer surface. The outer surface may include a fused area formed with a thermoformed thermoplastic material included with a first yarn. The inner surface may be at least partially formed with the second yarn and may substantially exclude the thermoplastic material.

Abstract: A wireless output device for connecting to a wireless local area network and receiving digital content from servers over a network that includes the Internet is herein disclosed and enabled. The wireless output device may include, among others, a television, a speaker, a projector, or an output controller. The wireless output device includes an interface and wireless communication units. The wireless communication units of the wireless output device may receive information from a portable electronic device. The wireless output device may further receive the digital content from one or more application servers or content servers operated over the Internet by a digital content service. The digital content may include audio digital content or video digital content. The output device may process the received digital content and render the processed digital content onto a display medium.

Abstract: The present disclosure describes a method of treating immunological disorders, for example alloimmune and autoimmune diseases, using a pharmaceutical composition comprising at least one mesenchymal stromal cell-derived protein Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.

Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.

Abstract: The present disclosure describes a pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein. Disclosed herein is also the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases. Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.

Abstract: The present invention relates to substituted azole derivatives in combination with cytokines in the ex vivo expansion of CD34+ hematopoietic stem and progenitor cells (HSPC) in a biological sample, more particularly the expansion of these cells obtained from non-enriched, i.e., the mononuclear fraction of the biological sample. The present invention further describes the transplantation regimen of the expanded hematopoietic graft developed through xenotransplantation studies. In a preferred embodiment, the combination comprising the azole based compounds and cytokines selected from SCF, TPO, FLT-3L and IGFBP-2 and results in the expansion of expansion of CD45+CD34+CD38?CD45RA?CD90+ hematopoietic stem cells and/or CD45+CD34+CD38?CD45RA?CD90+CD49f+ hematopoietic stem cells and/or CD45+CD34+CD38?CD45RA? hematopoietic progenitor cells from the mononucleated cells isolated from umbilical cord blood.

Abstract: The present disclosure describes a pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein. Disclosed herein is also the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases. Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.

Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

Abstract: Anonymous voice communication between a first station and a second station is facilitated by providing an interface that allows input of a transaction specification from at least one of the first and second stations. A reference code associated with the transaction is generated, there being a defined relationship between the reference code and the address of the second station for voice communication. The reference code is supplied to the first station, and a voice communication request and the reference code are received from the first station. The reference code is used to recover said address and a channel for voice communication is opened between said first and second stations. Voice communication can thereby be established between the first and second stations without providing the address of the second station to the first station.An Internet-based service system for data mining user information is herein disclosed and enabled.